Skip to main content
. 2009 Oct 28;90(6):1623–1631. doi: 10.3945/ajcn.2009.28319

TABLE 5.

Risk ratios (RRs) for recurrent adenoma by intervention group: stratified analyses of the Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS) Folic Acid Prevention Trial1

At least one adenoma
Stratification variable Placebo Folic acid Risk ratio (95% CI) P value
no. cases/total n no. cases/total n
Age
 ≤66 y 42/130 33/133 0.79 (0.54, 1.17) 0.24
 >66 y 30/108 29/104 1.00 (0.64, 1.55) 0.99
Aspirin
 <2 tablets/wk 38/139 33/134 0.88 (0.59, 1.32) 0.54
 ≥2 tablets/wk 34/99 29/103 0.85 (0.56, 1.30) 0.46
BMI
 ≤25 kg/m2 36/115 26/120 0.66 (0.43, 1.03) 0.06
 >25 kg/m2 36/123 36/117 1.08 (0.73, 1.59) 0.72
Smoking status
 Never 27/96 24/88 1.03 (0.64, 1.66) 0.89
 Ever 45/141 37/145 0.79 (0.54, 1.14) 0.21
Folate concentrations at baseline
 ≤7.5 ng/mL 42/113 32/139 0.61 (0.42, 0.90) 0.01
 >7.5 ng/mL 30/124 30/98 1.28 (0.82, 1.99) 0.27
Alcohol intake
 ≤5.6 g/d 31/117 33/122 1.00 (0.65, 1.53) 1.00
 >5.6 g/d 41/121 29/115 0.76 (0.51, 1.13) 0.17
Combination alcohol intake/folate baseline
 ≤5.6 g/d and gt7.5 ng/mL 14/62 15/53 1.23 (0.64, 2.37) 0.53
 >5.6 g/d and le7.5 ng/mL 25/59 14/70 0.49 (0.28, 0.84) 0.009
1

RRs were calculated by using a generalized linear model with a natural logarithm link function and Poisson distributed errors, which were adjusted for over- and underdispersion. Models included age at start of trial, sex, length of trial (3 compared with ≤6.5 y), and time between start of trial and last endoscopy (mo). All P values for interaction were >0.05, except for folate at baseline (P = 0.01) and combination alcohol/folate at baseline (P = 0.03).